Clearwater Paper Corporation — Q2 2022 Form 10-Q
Business context and reporting period. The filing covers the quarter and six months ended June 30, 2022. Clearwater Paper operates Pulp and Paperboard and Consumer Products segments. Results are unaudited; interim results are not necessarily indicative of full-year performance.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net sales | $526.4 million | $406.4 million | $1,014.6 million | $832.3 million |
| Operating income (loss) | $31.5 million | $(56.6) million | $64.4 million | $(29.5) million |
| Net income (loss) | $14.7 million | $(51.6) million | $31.3 million | $(39.6) million |
| Diluted EPS | $0.86 | $(3.10) | $1.83 | $(2.37) |
| Adjusted EBITDA | $63.0 million | $14.8 million | $121.9 million | $69.1 million |
| Operating cash flow | $78.5 million | $14.3 million | $119.5 million | $48.1 million |
Q2 operating margin was approximately 6.0% (versus a 13.9% operating loss margin a year earlier); net margin was approximately 2.8% (versus a 12.7% net loss margin). For the six-month periods, operating margin was approximately 6.3% versus a 3.5% loss margin, and net margin approximately 3.1% versus a 4.8% loss margin.
At June 30, cash and cash equivalents were $69.5 million; total debt was $590.9 million, including $1.0 million current and $589.9 million long-term. The company had repaid its $30 million term loan and reported no ABL borrowings; the $250 million revolving facility had $3.7 million of letters of credit outstanding and was subject to borrowing-base limits. The ABL covenant requires a 1.10x fixed-charge coverage ratio if unused availability falls below $25 million; the reported ratio was approximately 4.20x. Six-month capital expenditures were $13.2 million. Total liabilities were $1,168.0 million and stockholders’ equity was $544.7 million.
Material changes and operating drivers
- Quarterly sales increased 30%; six-month sales rose 22%. Management attributed growth to price increases and higher volumes, with increased demand and improved product availability supporting Pulp and Paperboard results.
- Pulp and Paperboard Q2 sales rose 30% and operating income increased to $52.0 million from $13.0 million. Paperboard shipments rose 7.7% and average selling price rose 25.9% year over year.
- Consumer Products Q2 sales increased 28.5%, while operating income was $3.5 million versus a $10.0 million loss. Retail tissue shipments rose 24.6% and selling price per short ton rose 8.3%. For the first six months, Consumer Products operating income fell to $4.4 million from $7.9 million and Adjusted EBITDA fell to $35.3 million from $41.4 million.
- Higher prices and volumes were partly offset by inflation and higher input costs, particularly pulp and transportation. Corporate expenses increased to $18.2 million in Q2 from $15.0 million, primarily due to higher incentive compensation.
- The prior-year comparison included $41.7 million of Neenah facility closure and impairment costs. Q2 2022 included $4.6 million of equipment impairment related to a closed facility and $1.1 million of directors’ equity-compensation expense. Q2 interest expense was higher, partly due to a one-time $2.2 million capital-lease adjustment.
Outlook, risks, and other disclosures
Management expected 2022 cash capital expenditures of approximately $45 million to $55 million. The filing provides no clear full-year revenue or earnings guidance. Management cited inflation, raw-material and transportation costs, competitive pricing, customer demand and product acceptance, supply-chain constraints, operational disruptions, labor, cybersecurity, and substantial indebtedness among relevant risks. The company reported no material change to the risk factors in its 2021 Form 10-K.
Management said disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter. The company stated that pending claims and proceedings, based on information then available, were not expected in aggregate to have a material adverse effect on financial condition.
Important facts for investors to verify
- Whether price increases and volume gains can continue to offset inflation and other input-cost pressures, especially in Consumer Products.
- Customer acceptance, quality, and utilization of tissue from the expanded Shelby operations, and the effects of the exit from the away-from-home tissue business.
- Debt repayment plans, ABL borrowing-base availability, covenant headroom, and the company’s ability to service its debt.
- Delivery of the stated $45 million to $55 million 2022 capital-spending plan and the operating benefits expected from those investments.
- The nature and potential financial impact of litigation, contingencies, or further asset impairments; the filing does not provide a clear quantified estimate of potential exposure.